Jasper Therapeutics–Kira Merger Rewrites $JSPR: $132M PIPE, 653.6M Shares and Why a Reverse Split Looks Increasingly Likely

What Jasper actually announced

After the U.S. market closed on July 16, Jasper announced that it had completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. Kira was a private, clinical-stage biotechnology company developing therapies that modulate the complement system in immune-mediated diseases. Jasper remains the listed legal entity, and the combined company is expected to continue trading on the Nasdaq Capital Market under the existing $JSPR symbol.

The acquisition closing and the financing closing are related but not identical events. Jasper said the Kira acquisition had already been completed, while the approximately $132 million private placement was expected to close on July 20, 2026, subject to customary conditions. Until that financing closes, the gross proceeds are committed but not yet cash on the combined company’s balance sheet.

The public company’s scientific center of gravity is also changing. Before the transaction, Jasper had narrowed itself around briquilimab and had begun reviewing strategic alternatives because of an imminent financing need. Following the merger, the lead value proposition expands to include Kira’s KP-104, a dual-pathway complement inhibitor with clinical data in paroxysmal nocturnal hemoglobinuria, or PNH, and ongoing development in rare renal disorders. Briquilimab remains part of the portfolio, but it is now one of three highlighted core assets rather than the sole organizing thesis.

The transaction structure, step by step

1. Kira equity was exchanged for Jasper securities

All outstanding Kira equity interests were exchanged for a combination of Jasper voting common stock and Jasper non-voting convertible preferred stock. The July 16 Form 8-K furnished the press release under Item 7.01 but did not attach a full merger agreement, certificate of designation, CVR agreement or securities purchase agreement. As a result, the public announcement provides the ownership outcome but not every contractual detail behind the exchange.

2. The PIPE uses non-voting convertible preferred stock

Jasper agreed to sell approximately 4.7 million preferred shares for approximately $132 million in gross proceeds. The financing was co-led by Affinity Asset Advisors and Ikarian Capital. Other disclosed participants include Columbia Threadneedle Investments, Sirenia Capital Management, Brahma Capital, Balyasny Asset Management, SilverArc Capital, Squadron Capital Management, Nazare Partners, Mirador Therapeutics, other life-sciences investors and certain members of Kira management.

Subject to Jasper stockholder approval under Nasdaq rules, each preferred share will automatically convert into 61 common shares, subject to beneficial-ownership limitations. Those limitations can delay how much common stock a particular holder can beneficially own at one time, but they do not eliminate the underlying dilution represented by the convertible securities.

The figures disclosed by Jasper are rounded, so the 4.7 million preferred-share estimate does not reconcile perfectly with the 43.46% PIPE ownership and 653.6 million total share count. The correct conclusion is therefore an approximate one: the financing was struck at roughly $0.46 per as-converted common share. JSPR closed at $0.774 on July 16 before the merger announcement, meaning the PIPE’s approximate common-equivalent price was materially below the public-market close. That discount must be viewed alongside the preferred stock’s non-voting status before conversion, closing conditions, beneficial-ownership caps and the risks of financing a company that had recently disclosed substantial doubt about its ability to continue as a going concern.

3. Stockholders must approve the conversion

The preferred stock cannot simply convert in full without a stockholder vote. Jasper said it is required to hold a meeting to seek approval under Nasdaq rules. This matters because the transaction creates potential common-stock issuance far beyond the company’s pre-deal share count and changes effective control of the listed entity.

As of March 31, Jasper had 492 million authorized common shares, approximately 28.0 million common shares outstanding and approximately 17.9 million additional common shares reserved for options, warrants and equity plans. The newly disclosed 653.6 million-share as-converted total is larger than the number of common shares then authorized. Before all preferred shares can become common stock, Jasper will need sufficient authorized-share capacity. That can be created by increasing the authorized common-share count, implementing a reverse split that proportionally reduces the common equivalents, or using some combination of corporate actions approved by shareholders.

Who owns the new $JSPR?

The difference between Jasper’s approximately 28.0 million common shares outstanding before the deal and the roughly 43.7 million common-equivalent legacy stake is explained by the use of a fully diluted calculation. Legacy options, pre-funded warrants, common warrants, public warrants and other equity-linked instruments must be considered when comparing like with like.

Percentage ownership dilution is severe: legacy Jasper equityholders move from owning the entire pre-transaction company to approximately 6.68% of the combined company. That does not automatically mean that 93.32% of economic value has been destroyed. Those holders now own a smaller percentage of a company that is receiving Kira’s assets and substantial new cash. The correct question is whether the value added by Kira, the $132 million financing and the $12 million licensing payment ultimately exceeds the value surrendered through dilution.

What valuation is embedded in the deal?

Jasper did not publish a dollar purchase price for Kira, but the cap table allows an approximate implied-value reconstruction. If $132 million buys 43.46% of the fully diluted combined company, the transaction implies a post-money equity value of roughly $304 million. Applying the disclosed ownership percentages produces the following approximate allocation:

These are Merlintrader calculations derived from rounded ownership percentages and the announced gross financing. They are not company guidance, a fairness opinion, an enterprise-value calculation or a disclosed acquisition price. Transaction expenses, the exact pre-closing cash positions, liabilities, milestone obligations and other adjustments can materially affect economic value.

Why Jasper accepted only 6.68%

The deal must be read against Jasper’s financial position before the merger. At March 31, 2026, Jasper reported only $14.1 million of cash and cash equivalents. It used $14.5 million of cash in operating activities during the first quarter alone. The company had an accumulated deficit of $317.8 million and concluded that substantial doubt existed about its ability to continue as a going concern for the following twelve months.

The first-quarter accounting net loss of $1.2 million understated the operating pressure because it included a $9.6 million non-cash gain from a decline in the fair value of warrant liabilities. Jasper’s operating loss was $11.0 million. In other words, the business did not suddenly become close to break-even; the reported net loss was heavily influenced by warrant accounting.

On June 1, the board initiated a formal strategic review that explicitly included asset sales, licensing, collaborations, a sale of the company, a merger, another business combination or an orderly wind-down. The Kira transaction is the selected outcome of that process. From that perspective, the 6.68% stake is not simply the price of adding a new pipeline. It is also the price of obtaining a funded path forward for a company that had disclosed an imminent need for capital and had placed a wind-down among its possible alternatives.

The CVR: a separate attempt to preserve briquilimab value

Each Jasper common stockholder immediately before the transaction closing is entitled to a non-transferable contingent value right, or CVR. The CVR can generate an aggregate payment of up to $30 million related to Jasper obtaining a priority review voucher for briquilimab by December 31, 2028.

The condition is narrower than “briquilimab succeeds.” Jasper must obtain the PRV by the deadline, and payment becomes due only upon monetization of the CVR or if the combined company is acquired after receiving the PRV. The company explicitly warns that CVR holders may never receive proceeds.

A simple division of the $30 million headline amount by Jasper’s approximately 28.0 million pre-deal common shares produces a nominal maximum of roughly $1.07 per currently outstanding common share. That is only a rough reference point. The complete CVR agreement was not attached to the July 16 Form 8-K, and the final per-right economics can depend on the exact number of eligible shares or rights, transaction costs, deductions, taxes, definitions and payment mechanics. The $1.07 figure must not be treated as cash already earned or as a guaranteed floor under JSPR.

The CVR also explains a strategic reversal inside the pipeline. Jasper’s March 2026 filing said it had substantially discontinued the SCID program in 2025. The combined company now plans to advance briquilimab in SCID toward a pre-BLA meeting and announce next steps in the first quarter of 2027. The asset that had been deprioritized for cash-preservation reasons becomes the foundation of a potential CVR payment to legacy holders.

Why a reverse stock split now looks increasingly likely

The strongest case for a future reverse split does not come from share-count aesthetics. It comes from an existing Nasdaq compliance problem.

On June 3, 2026, Jasper received a Nasdaq notice stating that JSPR had closed below the required $1 minimum bid price for 30 consecutive business days. The company has until November 30, 2026 in its initial 180-day compliance period. To regain compliance, the bid price generally must close at or above $1 for at least ten consecutive business days, although Nasdaq can require a longer period.

Jasper stated in its own filing that it would monitor the share price and consider available remedies, including a reverse stock split. If compliance is not restored by November 30, the company may qualify for another 180-day period, but that extension is not automatic and would require it to satisfy the other applicable listing standards and notify Nasdaq of its intention to cure the deficiency, including through a reverse split if necessary.

The 653.6 million-share count adds a second reason

The merger’s fully diluted, as-converted share count is approximately 653.6 million. That is not inherently bad—share count alone does not determine valuation—but it is unwieldy for a small clinical-stage biotechnology company and exceeds the 492 million authorized common shares disclosed in Jasper’s latest quarterly filing. A reverse split could simultaneously:

• raise the quoted share price to address the Nasdaq minimum-bid deficiency;
• reduce the number of common shares and common equivalents after conversion;
• create additional authorized-share headroom without necessarily increasing the authorized-share ceiling; and
• produce a capitalization more typical of an institutionally financed clinical-stage biotech.

Jasper has already used this tool once

On January 4, 2024, Jasper implemented a 1-for-10 reverse stock split to regain compliance with the same $1 Nasdaq minimum-bid requirement. The split reduced outstanding common shares from approximately 111.6 million to approximately 11.2 million. The company’s subsequent financing activity and the Kira transaction have rebuilt the fully diluted share count on a much larger scale.

The ratios above are illustrations, not predictions. Jasper has not announced a new reverse split, selected a ratio, disclosed a vote on a ratio range or set an effective date. A reverse split changes the number of shares and the quoted price per share proportionally; by itself, it does not change a holder’s percentage ownership or the company’s intrinsic value. Market prices can nevertheless move before or after a split because of sentiment, liquidity and subsequent financing.

The new combined pipeline

KP-104 / vensobafusp alfa: the new lead complement asset

KP-104 is a bifunctional biologic designed to inhibit both the alternative and terminal complement pathways. Its Factor H domain acts proximally around the alternative-pathway amplification loop, while its anti-C5 component inhibits the terminal pathway. Kira’s thesis is that dual inhibition may control both intravascular and extravascular hemolysis in diseases where single-pathway inhibition can leave residual activity.

In Kira’s small Phase 2 study in complement-inhibitor-naïve PNH patients, 18 patients treated subcutaneously were included in the December 2024 update. Kira reported that all 18 achieved at least a 2 g/dL hemoglobin increase from baseline, 16 of 18 achieved hemoglobin normalization of at least 12 g/dL, 17 of 18 achieved LDH below 1.5 times the upper limit of normal, and all remained free from red-blood-cell transfusions through weeks 84/85 of total treatment.

Those results are encouraging but should not be overextended. The dataset was small, non-randomized and generated in a selected clinical population. The decisive value test will be the design agreed with regulators, the comparator used in a registrational program, durability and safety at larger scale, and whether dual inhibition delivers a commercially meaningful advantage in an increasingly competitive PNH market.

The combined company plans an end-of-Phase 2 FDA meeting for PNH and expects to announce next steps during the first half of 2027. It also expects to name an additional KP-104 indication by the end of 2026.

KP-104 in rare renal disease

KP-104 is also being evaluated in a Phase 2 basket study in complement-mediated renal diseases. Historical Kira development plans included IgA nephropathy, C3 glomerulopathy and thrombotic microangiopathy associated with systemic lupus erythematosus. Jasper’s transaction announcement did not provide patient-level renal data or fully restate the current cohort composition, so investors should wait for the upcoming presentation before assuming that every earlier Kira indication remains active.

The next disclosed readouts are interim Stage 1 data in the fourth quarter of 2026, updated Stage 1 data in the second quarter of 2027 and interim Stage 2 data in the second quarter of 2027. These renal results are among the first major tests of whether Kira’s platform can create a multi-indication franchise rather than a single PNH program.

Briquilimab: retained, repositioned and partly protected by the CVR

Briquilimab is an aglycosylated anti-KIT monoclonal antibody designed to block stem cell factor signaling through KIT and deplete mast cells or facilitate conditioning in selected transplant settings. Jasper had generated encouraging early clinical signals in chronic spontaneous urticaria and chronic inducible urticaria but entered 2026 with limited cash and a shrinking ability to fund broad development.

The combined company now plans two parallel decisions. First, it will provide an update on the mast-cell-disease development strategy in the second half of 2026. Second, it is advancing the SCID regulatory work toward a pre-BLA meeting, with next steps expected in the first quarter of 2027. The latter pathway is the one directly connected to the legacy-holder CVR and potential PRV value.

KP-701: the earlier-stage option

KP-701 is described as a dual-acting anti-CD79B×CD32B monoclonal antibody for autoantibody-mediated disorders. It remains preclinical. The combined company expects to file a CTA or IND for Phase 1 testing in the first quarter of 2027 and report first-in-human data in the third quarter of 2027. Its inclusion broadens the immunology pipeline, but current valuation should reflect the substantially higher attrition risk attached to a preclinical program.

KP-301 and KP-402 move to Mirador

Kira out-licensed KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small-molecule C5a receptor antagonist, to Mirador Therapeutics. The agreement provides $12 million upon signing plus potential development and sales milestones. Jasper did not disclose the milestone totals, royalty economics, development-cost responsibilities or termination provisions in the July 16 announcement.

The licensing decision narrows the combined company’s internal spending to KP-104, briquilimab and KP-701 while allowing the C5a programs to continue elsewhere. Mirador’s participation in the PIPE also creates a relationship that extends beyond a conventional arm’s-length license, although the public materials do not establish that Mirador controls the broader transaction.

Management and board control

Jeet Mahal remains President and Chief Executive Officer, and Herb Cross remains Chief Financial Officer. Greg Keenan becomes Chief Medical Officer; Matthew Ros is Chief Operating Officer; and Kira’s Wenru Song becomes Executive Vice President and Head of Research and Development.

The combined board is expected to include Patrick Crutcher, Jeet Mahal, Thomas Wiggans, Judith Shizuru, Svetlana Lucas and Kurt von Emster. The ownership and board composition confirm that this is not a conventional acquisition in which Jasper simply absorbs a smaller target. Economically, it resembles a private-company pipeline recapitalization using Jasper’s Nasdaq listing, corporate infrastructure and briquilimab asset.

Catalyst and corporate-action calendar

What remains undisclosed or uncertain

• The exact number of common and preferred shares issued to each Kira holder.
• The complete merger consideration mechanics and any post-closing adjustments.
• The detailed rights, preferences, protective provisions and registration rights attached to the new preferred stock.
• The exact stockholder-vote proposals, including whether Jasper will request an authorized-share increase, reverse-split authority or both.
• The final reverse-split ratio, timing and effective date—because none has been announced.
• The full CVR agreement, including detailed payment waterfall, deductions and dispute provisions.
• The total potential milestones and royalties under the Mirador license.
• Kira’s latest standalone cash balance, liabilities, operating burn and program-level spending.
• The exact Phase 3 design, comparator, size, timing and cost for KP-104 in PNH.
• Whether the combined company will retain all legacy Jasper mast-cell programs or further narrow the briquilimab strategy.

These gaps are not minor. The July 16 Form 8-K contains only a short Item 7.01 disclosure and the furnished press release. The proxy statement, registration statement and any subsequent material-agreement filings should provide a more complete basis for judging governance, conversion mechanics and the true cost of the transaction.

Bull, neutral and bear interpretations

What investors should watch next

The immediate confirmation is the July 20 PIPE closing. After that, the most important document will be the stockholder proxy or registration filing explaining the exact preferred conversion, authorized-share requirement and any reverse-split proposal. Trading headlines about a 653.6 million share count are not enough; the market needs to see how and when those equivalents become freely tradable common shares, which holders are subject to ownership caps or lockups, and what registration rights have been granted.

The second priority is scientific. KP-104 now carries much of the combined company’s implied value, and the Q4 2026 renal data will test whether the strong PNH signal translates into additional complement-mediated diseases. The third is regulatory: the briquilimab SCID pre-BLA path will determine whether the CVR has a realistic route toward value before the December 2028 deadline.

Legacy analyst price targets and historical per-share comparisons should be treated cautiously. The company’s pipeline, ownership, cash balance and fully diluted capitalization are all changing at once. Any meaningful valuation must be rebuilt on the post-transaction share count and then adjusted for whatever reverse split or authorized-share amendment is ultimately approved.

Bottom line

The Kira transaction rescues Jasper from an immediate liquidity problem and replaces a shrinking, single-asset strategic story with a funded immunology and complement platform. That is the constructive side of the deal. The cost is equally clear: pre-transaction Jasper equityholders are expected to own only 6.68% of the combined company, while Kira holders and PIPE investors control the other 93.32% on a fully diluted, as-converted basis.

The disclosed 653.6 million-share structure is not a clerical detail. It reveals the scale of the recapitalization, creates an authorized-share issue that must be resolved before full conversion and strengthens the practical case for another reverse stock split. Because Jasper is already below Nasdaq’s minimum bid standard and has named a reverse split as a possible cure, the scenario is more than casual speculation. But no ratio or effective date exists yet, and an authorized-share increase remains another available route.

Ultimately, the deal will not be judged by whether JSPR trades with 653.6 million shares, 65.4 million shares after a hypothetical 1-for-10 split or some other number. It will be judged by whether KP-104, briquilimab and KP-701 generate enough clinical and regulatory value to justify the approximately $304 million post-money framework embedded in the transaction—and whether the new capital lasts long enough to reach those proof points.

Primary sources

• Jasper Therapeutics Form 8-K filed July 16, 2026
• Jasper Therapeutics merger and financing announcement
• Jasper Form 8-K: Nasdaq minimum-bid deficiency notice
• Jasper Form 10-Q for the quarter ended March 31, 2026
• Jasper strategic-alternatives announcement dated June 1, 2026
• Jasper’s January 2024 reverse stock split announcement
• Kira Pharmaceuticals: KP-104 mechanism and development overview
• Kira’s updated Phase 2 KP-104 PNH data presented at ASH 2024
• ClinicalTrials.gov: KP-104 Phase 2 PNH study NCT05476887
• Nasdaq continued-listing and reverse-stock-split disclosure rules
• Nasdaq market data page for JSPR